Maroni, GiorgiaTomassi, ElenaValenti, DonatellaFernàndez-Busquets, XavierPucci, LauraLevantini, ElenaCaddeo, Carla2026-01-272026-01-272024-05-250378-5173https://hdl.handle.net/2445/226231New drugs and technologies are continuously developed to improve the efficacy and minimize the critical side effects of cancer treatments. The present investigation focuses on the development of a liposomal formulation for Idelalisib, a small-molecule kinase inhibitor approved for the treatment of lymphoid malignancies. Idelalisib is a potent and selective antitumor agent, but it is not indicated nor recommended for first-line treatment due to fatal and serious toxicities. Herein, liposomes are proposed as a delivery tool to improve the therapeutic profile of Idelalisib. Specifically, PEGylated liposomes were prepared, and their physicochemical and technological features were investigated. Light-scattering spectroscopy and cryo-transmission electron microscopy revealed nanosized unilamellar vesicles, which were proved to be stable in storage and in simulated biological fluids. The cytotoxicity of the liposome formulation was investigated in a human non-Hodgkin's lymphoma B cell line. Idelalisib was able to induce death of tumor cells if delivered by the nanocarrier system at increased efficacy. These findings suggest that combining Idelalisib and nanotechnologies may be a powerful strategy to increase the antitumor efficacy of the drug.7 p.application/pdfengcc-by (c) Maroni, Giorgia et al., 2024https://creativecommons.org/licenses/by/4.0/Transformació limfocitàriaCèl·lules epitelialsAntígens tumoralsLymphocyte transformationEpithelial cellsTumor antigensinfo:eu-repo/semantics/article2026-01-15info:eu-repo/semantics/openAccess661012438653342